Administration of synthetic GSH, such as hexarelin and GHRP-6, have also demonstrated improvements in patients and animals with ischemic cardiomyopathy or dialated cardiomyopathy (DCM), independent of IGF-1 [71-75]. This evidence concerns the gene IGF1 and familial dilated cardiomyopathy.